Class summary at a glance.

Every drug in the Non-Benzodiazepine Hypnotic (Z-Drug) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $155.9Mcombined across class
Total Rx claims: 13.3M3.2M unique beneficiaries
Generic mfrs (active): 22across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Zolpidem

Brand: Ambien · 12.0M Part D claims (CY24) · 2.9M beneficiaries · First FDA approval: 1993-04-01

12 generic mfrs 252 plans require PA

Low NADAC$0.035

→

Avg plan cost$2.54

Part D spend $120.3M 73× spread, current vs floor

Class share

77%

of class CY24 spend

View profile →

Eszopiclone

Brand: Lunesta · 1.3M Part D claims (CY24) · 352K beneficiaries · First FDA approval: 2013-03-26

10 generic mfrs 112 plans require PA Discontinued

Low NADAC$0.085

→

Avg plan cost$0.090

Part D spend $35.6M 1× spread, current vs floor

Class share

23%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.